Cleanroom Technician
About the job
- Able to understand, retain, and effectively apply on-the-job training instruction.
- Consistently follow processes and procedures to operate compliantly within a controlled environmental manufacturing space.
- Read and understand assembly drawings and assembly instructions to correctly and efficiently assemble products.
- Distinguish differences in sub-component parts based on part number and visual inspection.
- Perform in-process inspections per applicable specifications or work orders, including inspection of input and output materials and packaging integrity.
- Consistently adhere to assembly methodology and accept/reject criteria.
- Consistently comply with policies, guidelines, and regulatory requirements of the Carolina Components Quality System.
- Interact with Quality Assurance personnel to ensure product quality and address detected non-conformities.
- Report problems with quality, processes, equipment, or materials to the Team Lead or Supervisor.
- Utilize approved tools and fixtures safely and efficiently.
- Complete line clearance, scrap records, training records, and other required documentation.
- Maintain batch records for traceability in accordance with documented company standards.
- Maintain a clean and organized work area.
- Read and comprehend procedures written in English.
- Complete paperwork accurately in English.
- Work safely around chemicals and equipment.
- Stand or sit for long periods.
- Perform repetitive work requiring strong dexterity and hand-eye coordination.
- Lift up to 40 pounds.
- Assemble, test, inspect, and package single-use assemblies using assembly equipment, tools, and test equipment within a controlled-environment assembly setting.
- Perform labeling and packaging activities.
- Maintain batch records and required documentation for product traceability.
- Perform other duties as assigned by the Supervisor or Team Lead.
- Previous work experience within a controlled environmental space.
- Previous assembly experience.
About the company
Carolina Components Group provides ultra-pure processing equipment and fluid handling solutions for pharmaceutical, biotech, and cell & gene therapy manufacturing. It designs, manufactures, distributes, and custom-engineers single-use components and assemblies, and operates ISO 7/8 cleanrooms for single-use manufacturing. Its product range includes aseptic connectors, filters, fittings, sensors, gaskets, hoses, tubing, valves, and FlowLinX, FlowPress, FlowMixer, and Sidewinder Clamp, plus design consulting and asset management via TESSALink CertNet. The company differentiates itself through veteran leadership, private-equity backing, integrated components and engineering services, in-house cleanrooms, and partnerships with suppliers like NewAge Industries and Qosina to support scalable, compliant biopharma manufacturing.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Chapel Hill, North Carolina
Founded
2020
Get referred to Carolina Components Group
See people who can refer or advise you
Simplify's Take
What believers are saying
- Sheridan’s August 4, 2026 investment provides capital for acquisitions, capacity, and sales expansion.
- CCG reported over 250 biopharmaceutical and contract manufacturing customers, signaling broad market traction.
- John Cooling and Maik Jornitz joining the board strengthen credibility with regulated manufacturing buyers.
What critics are saying
- Sheridan’s August 2026 acquisition installs Maurice Phelan, forcing a new operating model quickly.
- Sartorius, Cytiva, and Repligen can bundle broader platforms and squeeze CCG on accounts.
- Customer concentration in biopharma manufacturing ties revenue to validation cycles and plant buildouts.
What makes Carolina Components Group unique
- Founded by John Cooling in 2020, CCG sells custom-engineered single-use assemblies, not catalog parts.
- Durham cleanrooms and ISO 7/8 manufacturing support regulated biopharma customers needing validated sterility.
- FlowLinX, FlowPress, and FlowMixer combine proprietary products with design, labeling, and asset management.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%MDermott Will & Schulte advises Carolina Components Group in investment by Sheridan Capital Partners. Aug 5, 2026 Read time: 2 min Global law firm MDermott Will & Schulte represented Carolina Components Group (CCG), a provider of custom-engineered bioprocessing assemblies and components used in the manufacturing of biopharmaceuticals, in connection with an investment by Sheridan Capital Partners (Sheridan). Founded in 2020 and headquartered in Durham, North Carolina, CCG supplies ultra-pure components, custom-engineered single-use assemblies, and process solutions that support highly regulated biopharmaceutical production environments for more than 250 biopharmaceutical and contract manufacturing customers.
Sheridan Capital Partners has completed its investment in Carolina Components Group, a Durham, North Carolina-based supplier of custom-engineered bioprocessing assemblies and components to biopharmaceutical manufacturers. Financial terms were not disclosed. Founded in 2020, CCG serves over 250 biopharmaceutical and contract manufacturing customers with ultra-pure components and process solutions for regulated production environments. Maurice Phelan has been appointed as the company's new chief executive officer. Phelan previously served as president of Sartorius North America and held executive positions at GE Lifesciences, Repligen, and Merck Millipore. CCG founder John Cooling will join the board of directors whilst retaining ownership alongside other company leaders. Bioprocessing industry veteran Maik Jornitz will also join the board. Houlihan Lokey served as financial adviser to CCG, whilst Kirkland & Ellis advised Sheridan.
Sheridan Capital Partners completes investment in Carolina Components Group, a key supplier to biopharmaceutical manufacturers. Industry Leader Maurice Phelan Named CEO; Founder John Cooling and Bioprocessing Veteran Maik Jornitz Join Board CHICAGO, IL - August 4, 2026 - Sheridan Capital Partners ("Sheridan") today announced the completion of its investment in Carolina Components Group ("CCG" or the "Company"), a provider of custom-engineered bioprocessing assemblies and components used in the manufacturing of biopharmaceuticals. Concurrent with the investment, CCG has named Maurice Phelan as the Company's new CEO. CCG Founder John Cooling will join the Board of Directors while he and other CCG leaders remain meaningful owners of the Company. Founded in 2020 and headquartered in Durham, North Carolina, CCG supplies ultra-pure components, custom-engineered single-use assemblies, and process solutions that support highly regulated biopharmaceutical production environments for over 250 biopharmaceutical and contract manufacturing customers. As a customer-service-focused partner, CCG leverages its extensive experience and bioprocessing expertise to address growing industry demand and new technology requirements. "The team at CCG has worked extremely hard to develop our reputation as a high-quality provider of custom solutions to our customers," said CCG Founder and Board Member, John Cooling. "We are excited to partner with Sheridan, whose operational resources and knowledge of our market will enable us to accelerate growth with our customers." "CCG is the result of our multi-year thesis in the pharmaceutical manufacturing supply chain, and we are very excited to be partnering with the Company at this inflection point," said Michael Bernard, Partner at Sheridan. New CEO Maurice Phelan brings extensive leadership experience in the bioprocessing sector to CCG, having most recently served as President of Sartorius North America. Mr. Phelan has also held executive leadership positions at other sector leaders including GE Healthcare Life Sciences (now Cytiva), Repligen, and Merck Millipore. "I am thrilled to be joining CCG and I look forward to partnering with the existing team and Sheridan to continue the Company's strong legacy of quality, expertise and deep customer focus," said Phelan. "With Sheridan's support and guidance, we are well-positioned to expand our offerings and deepen relationships across our diversified blue-chip customer base." Bioprocessing industry veteran and Sheridan Advisor Maik Jornitz will also join the CCG Board. "CCG stands out as a partner defined by quality, customer focus, and reliability, and I am very happy to join and support the company's exceptional growth trajectory," added Jornitz, who spent 25 years at Sartorius, including as a Senior Vice President, Bioprocess, and 10 years at G-CON Manufacturing, most recently as CEO. The transaction was led by Sean Dempsey, Michael Bernard, and Conor Kolstad at Sheridan Capital Partners. Kirkland & Ellis LLP served as legal counsel to Sheridan Capital Partners. Houlihan Lokey served as financial advisor and McDermott Will & Schulte LLP served as legal counsel to Carolina Components Group. About Sheridan Capital Partners. Sheridan Capital Partners is a private equity firm focused exclusively on partnering with businesses across the healthcare landscape, including outsourced services, products and manufacturing, providers, and software and technology. Sheridan's engaged operational approach brings strategic resources and deep industry expertise with the purpose of accelerating growth, building enduring value, and generating strong results. For more information, visit www.sheridancp.com/. About Carolina Components Group. Founded in 2020 and headquartered in Durham, North Carolina, CCG supplies ultra-pure components, custom-engineered assemblies, and process solutions that support highly regulated biopharmaceutical production environments. For more information, visit www.carolinaflow.com. This press release includes a statement provided by Maurice Phelan, Chief Executive Officer of CCG, a portfolio company of funds advised by Sheridan Capital Partners. Maurice Phelan is not a client or investor of Sheridan. The portfolio company relationship presents a potential conflict of interest, as Sheridan benefits from the success of its portfolio companies. No compensation was paid for this statement.